Search Bar & Filters
Found 32 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.
Actively Recruiting
Researchers are evaluating treatments for adults with high risk chronic lymphocytic leukemia CLL, a common and aggressive form of leukemia. The study compares a triple drug combination of acalabrutinib, obinutuzumab, and venetoclax GAVe against a dual combination of obinutuzumab and venetoclax GVe. This phase 3 trial aims to see if adding acalabrutinib can prolong the time patients live without disease progression, focusing on patients with specific genetic risk factors like 17p deletion, TP53 mutation, or complex karyotype. Participants receive infusions of obinutuzumab on specific days during the first six cycles, along with oral venetoclax taken daily with increasing doses during the initial cycles and then a fixed dose for up to 12 cycles. Those in the triple combination group also take oral acalabrutinib twice daily for cycles 15 to 24. Treatments are given in cycles lasting several weeks, with precise dosing schedules for each medication. During the study, participants undergo regular assessments including blood tests to monitor disease status and treatment effects. Researchers measure progression-free survival as the primary outcome, along with other outcomes such as minimal residual disease, overall response, survival rates, and time until next treatment. The study involves randomized assignment to treatment groups and continues through multiple cycles, with monitoring extending up to 50 months after the first patient is included.
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of inavolisib combination therapies in women with untreated, early-stage Stage II-III, PIK3CA-mutated, estrogen receptor-positive, HER2-negative breast cancer. This Phase II, open-label study focuses on patients suitable for neoadjuvant endocrine combination therapy and aims to better understand treatment options for this specific breast cancer subtype. Participants will be assigned randomly to different treatment groups where they will receive various combinations of oral inavolisib, letrozole, ribociclib, and giredestrant. Treatments are given in cycles, with initial cycles lasting 28 days, followed by a shorter 21-day cycle, adjusting the combination doses accordingly. The study includes multiple experimental arms, each with a specific regimen schedule over approximately six cycles. Throughout the study, participants will undergo regular assessments including monitoring of adverse events, tumor response evaluations, and biomarker changes such as Ki-67 levels. Patient-reported outcomes related to symptoms and treatment side effects will also be collected. Safety is tracked up to 30 days after the last dose, with the entire participation lasting about eight months to cover treatment and evaluation periods.
Actively Recruiting
Researchers are evaluating whether adding Acalabrutinib to the standard R-miniCHOP chemotherapy can improve progression-free survival in older adults with untreated diffuse large B-cell lymphoma DLBCL. This phase 3, randomized trial compares outcomes of patients receiving R-miniCHOP alone with those receiving R-miniCHOP plus Acalabrutinib. The study focuses on individuals 61 years and older who are ineligible for full-dose R-CHOP treatment. Participants will be randomly assigned to one of two groups one receiving 6 cycles of R-miniCHOP plus 2 doses of Rituximab, and the other receiving the same regimen combined with Acalabrutinib taken orally twice daily for 8 cycles. The chemotherapy cycles are repeated every 3 weeks, and the study is open-label, meaning both participants and researchers know which treatment is given. During the trial, participants will undergo regular assessments to monitor disease progression, survival, remission rates, and adverse events for up to 5 years. Researchers will evaluate blood tests, physical exams, and other health parameters to measure outcomes such as progression-free survival, overall survival, event-free survival, and treatment safety. The study aims to provide detailed information on long-term effects and treatment tolerability in this older patient population.
Actively Recruiting
Researchers are evaluating the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people with heart failure who have reduced ejection fraction. This registry study includes subjects recently implanted with the device under approved criteria for heart failure, specifically those with New York Heart Association NYHA functional Class III and left ventricular ejection fraction LVEF of 35% or less despite guideline-directed therapy. The study aims to understand how this therapy performs in a real-world commercial setting. Participants who received the BAROSTIM NEO System within 30 days before enrollment will be followed. Data will be collected from standard care measurements taken before implantation, at enrollment, and then at 3, 6, and 12 months after implantation. The study will track changes in heart failure severity, exercise capacity, heart function, biomarkers, device usage, and healthcare use such as hospitalizations related to heart failure. During the study, participants will undergo evaluations including assessments of their NYHA functional class, six-minute hall walk test, echocardiogram measurements, and blood tests for biomarkers like NT-pro BNP and Troponin HsT. Researchers will monitor hospitalizations over the 12-month follow-up. Each participant will complete the study after 12 months of monitoring following device implantation.
Actively Recruiting
Researchers are studying metastatic colorectal carcinoma mCRC patients who have a specific BRAFV600E mutation, which is linked to poorer outcomes compared to those without it. This mutation leads to shorter survival times after initial treatments, prompting the need for new therapy combinations. This research aims to observe how the drugs encorafenib and cetuximab work together in real-world settings for patients who have already received prior systemic therapies. This non-interventional, prospective, longitudinal study focuses on patients treated with encorafenib plus cetuximab following prior systemic therapy. The study collects data on treatment effectiveness, safety, and quality of life among a broader patient population in Germany, Austria, and Switzerland. Patients may have started treatment up to three months before joining the study or plan to start soon, and the study observes their outcomes without influencing treatment decisions. Participants will be monitored through data collection on their disease and treatment profiles, including patient and physician assessments, adverse events, and treatment details. The main outcome measured is overall survival at 12 months after starting treatment. Additional information gathered includes treatment duration, dose intensity, interruptions, and patient-reported quality of life using questionnaires. Safety and tolerability are also evaluated throughout treatment, with follow-up averaging nine months.
1-10 of 32
1